MacroGenics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

MacroGenics, a biopharmaceutical company focused on monoclonal antibody therapies for cancer, will participate in two investor conferences in February 2021. The first is the Guggenheim Healthcare Talks 2021 Oncology Day on February 11 at 11:30 AM ET, followed by the SVB Leerink 10th Annual Global Healthcare Conference on February 24 at 12:00 PM ET. Both events will be held virtually, and presentations can be accessed under the 'Events & Presentations' section on the MacroGenics website. Archived replays will be available for 30 days post-conference.

ROCKVILLE, MD, Feb. 08, 2021 (GLOBE NEWSWIRE) --  

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in February:

• Guggenheim Healthcare Talks 2021 Oncology Day. MacroGenics’ management is scheduled to participate in a fireside chat on Thursday, February 11, 2021 at 11:30 AM ET. The conference will be held in a virtual meeting format.
• SVB Leerink 10^th Annual Global Healthcare Conference. MacroGenics’ management is scheduled to participate in a fireside chat on Wednesday, February 24, 2021 at 12:00 PM ET. The conference will be held in a virtual meeting format.

Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.

About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

FAQ

What are the upcoming investor conferences for MacroGenics in February 2021?

MacroGenics will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11 at 11:30 AM ET and the SVB Leerink 10th Annual Global Healthcare Conference on February 24 at 12:00 PM ET.

How can I access the presentations from MacroGenics' investor conferences?

Presentations can be accessed under the 'Events & Presentations' section on MacroGenics' website.

Will MacroGenics provide replays of their investor conference presentations?

Yes, MacroGenics will maintain archived replays of the webcasts for 30 days after each conference.

What is MacroGenics' focus in the biopharmaceutical industry?

MacroGenics focuses on developing and commercializing innovative monoclonal antibody-based therapeutics for cancer treatment.

What is the stock symbol for MacroGenics?

The stock symbol for MacroGenics is MGNX.